Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,653 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Zhang L, Li P, Xing CY, Zhao JY, He YN, Wang JQ, Wu XF, Liu ZS, Zhang AP, Lin HL, Ding XQ, Yin AP, Yuan FH, Fu P, Hao L, Miao LN, Xie RJ, Wang R, Zhou CH, Guan GJ, Hu Z, Lin S, Chang M, Zhang M, He LQ, Mei CL, Wang L, Chen X. Zhang L, et al. Among authors: hu z. Am J Kidney Dis. 2014 Jul;64(1):57-65. doi: 10.1053/j.ajkd.2014.01.431. Epub 2014 Mar 14. Am J Kidney Dis. 2014. PMID: 24631042 Free article. Clinical Trial.
Prevalence of chronic kidney disease in China: a cross-sectional survey.
Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. Zhang L, et al. Among authors: hu z. Lancet. 2012 Mar 3;379(9818):815-22. doi: 10.1016/S0140-6736(12)60033-6. Lancet. 2012. PMID: 22386035
Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study.
Zheng Y, Cai GY, He LQ, Lin HL, Cheng XH, Wang NS, Jian GH, Liu XS, Liu YN, Ni ZH, Fang JA, Ding HL, Guo W, He YN, Wang LH, Wang YP, Yang HT, Ye ZM, Yu RH, Zhao LJ, Zhou WH, Li WG, Mao HJ, Zhan YL, Hu Z, Yao C, Wei RB, Chen XM. Zheng Y, et al. Among authors: hu z. Chin Med J (Engl). 2017 Oct 20;130(20):2402-2409. doi: 10.4103/0366-6999.216407. Chin Med J (Engl). 2017. PMID: 29052559 Free PMC article. Clinical Trial.
Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up Study.
Zheng Y, Wang NS, Liu YN, He LQ, Jian GH, Liu XS, Ni ZH, Cheng XH, Lin HL, Zhou WH, Wang YP, Fang JA, He YN, Yang HT, Zhao LJ, Ding HL, Wang LH, Yu RH, Li WG, Ye ZM, Guo W, Zhan YL, Mao HJ, Hu Z, Yao C, Cai GY, Chen XM. Zheng Y, et al. Among authors: hu z. Chin J Integr Med. 2019 Mar;25(3):168-174. doi: 10.1007/s11655-018-2998-y. Epub 2018 Nov 22. Chin J Integr Med. 2019. PMID: 30467695 Clinical Trial.
Activated YAP causes renal damage of type 2 diabetic nephropathy.
Ma R, Ren JM, Li P, Zhou YJ, Zhou MK, Hu Z, Xiao XY. Ma R, et al. Among authors: hu z. Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):755-763. doi: 10.26355/eurrev_201901_16890. Eur Rev Med Pharmacol Sci. 2019. PMID: 30720184 Free article.
20,653 results
You have reached the last available page of results. Please see the User Guide for more information.